Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

NCT ID: NCT05562362

Last Updated: 2022-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 47 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-18
• Study Completion Date: 2020-11-12

Brief Summary

This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels. In each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess Pharmacokinetics (PK) following multiple dosing.

Detailed Description

This is a single-center, open-label, randomized, single- and multiple-dose, 3-way sequential study at 3 dose levels in healthy subjects. For logistical purposes subjects will be admitted to the unit to be dosed in groups of approximately 16 or fewer. Subjects will be randomized into one of the three dose levels. Within each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess PK following multiple dosing.

Subjects will undergo preliminary screening procedures for the study at the screening visit (Day -28 to Day -2). Subjects will be admitted to the clinical unit on the evening prior to investigational medicinal product (IMP) administration (Day -1) and will remain on site until 72 h post-final dose. Subjects will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study day 1) and a single dose of sparsentan in the fed state (high-fat breakfast) on Period 2, Day 1 (Study day 8), followed by multiple doses of sparsentan in the fed state on Period 3, Day 1 to 14 (Study days 12 to 25). On PK sampling days for the multiple dose treatment period (Period 3, Days 7, and 14; Study days 18 and 25), subjects will consume a high-fat breakfast before dosing; on other days, a standard breakfast will be provided.

A follow-up phone call will take place 5 to 7 days post-final dose to ensure the ongoing wellbeing of the subjects.

Conditions

Healthy Subjects

Keywords

Focal Segmental Glomerulosclerosis (FSGS); Immunoglobulin A Nephropathy (IgAN)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fasted State

Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will be randomized to 1 of 3 dose levels (200mg, 400mg and 800 mg) and will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study Day 1)

Group Type: EXPERIMENTAL

RE-021, sparsentan

Intervention Type: DRUG

RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Fed State

Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have a single dose of sparsentan (200mg, 400mg and 800 mg) in the fed state (high-fat breakfast) on Period 2, Day 1 (Study Day 8)

Group Type: EXPERIMENTAL

RE-021, sparsentan

Intervention Type: DRUG

RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Fed State - Multiple

Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have multiple doses of sparsentan (200mg, 400mg and 800 mg) in the fed state on Period 3, Days 1 to 14 (Study days 12 to 25)

Group Type: EXPERIMENTAL

RE-021, sparsentan

Intervention Type: DRUG

RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Interventions

RE-021, sparsentan

RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy males or healthy females of non-childbearing potential

2. Between 18 and 55 years of age, inclusive, at time of signing informed consent

3. Body mass index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening

4. Must be willing and able to communicate and participate in the whole study

5. Must provide written informed consent

6. Must agree to adhere to the contraception requirements

Exclusion Criteria

1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1

2. Subjects who are or are immediate family members of a study site employee or a sponsor employee

3. Subjects who have previously been enrolled (dosed) in this study; subjects who have previously received sparsentan

4. Evidence current SARS-CoV-2 infection

5. History of any drug or alcohol abuse in the past 2 years

6. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)

7. A confirmed positive alcohol breath test at screening or admission

8. Current smokers and those who have smoked within the last 3 months

9. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission

10. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 3 months

11. Females of childbearing potential:

• A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone [FSH] concentration ≥40 IU/L)

12. Subjects who are pregnant or lactating and subjects with pregnant or lactating partners. All women must have a negative pregnancy test at admission

13. Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator or delegate at screening

14. Clinically significant abnormal clinical chemistry, hematology or urinalysis as judged by the investigator at screening

15. Serum alanine aminotransferase (ALT) > 1.5× upper limit of normal at screening

16. Serum potassium > upper limit of normal at screening

17. Confirmed positive drugs of abuse test result at screening or admission to Period 1

18. Corrected QT interval by Fridericia's formula (QTcF) greater than 450 msec; ventricular rate less than 40 per minute or greater than 90 per minute at screening or prior to dosing

19. For supine vital signs: systolic blood pressure less than 100 mmHg or greater than 140 mmHg (in subjects > 45 years of age up to 160 mmHg is acceptable); diastolic blood pressure less than 60 mmHg or over 90 mmHg at screening and pre-first dose.

20. Decrease in systolic blood pressure of 20 mmHg or more and/or decrease in diastolic blood pressure of 10 mmHg or more, measured after standing for approximately 2 to 5 min at screening and pre-dose in Period 1.

21. Increase in heart rate of over 30 bpm measured after standing for 2 to 5 min at screening and pre-dose Period 1

22. Any current or recent symptoms of postural hypotension or postural tachycardia at screening and pre-dose Period 1

23. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

24. Evidence of renal impairment at screening, as indicated by an eGFR of <90 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) (2009) equation

25. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator

26. Subjects with a history of cholecystectomy or gall stones

27. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

28. Subjects with a history of any hypersensitivity to angiotensin receptor blockers, endothelin receptor antagonists or the suspension formulation excipients

29. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active

30. Donation or loss of greater than 400 mL of blood within the previous 3 months

31. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than 4 g of paracetamol per day or hormone replacement therapy [HRT]) in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the PI

32. Use of any medication, eg erythromycin, itraconazole, and gestodene, that is known to inhibit CYP3A4 within 14 days before IMP administration

33. Use of any medication or substance known to induce CYP3A4, eg St John's Wort, within 30 days before IMP administration

34. Failure to satisfy the investigator of fitness to participate for any other reason

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Travere Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Travere Investigational Site

Nottingham, , United Kingdom

Countries

United Kingdom

Other Identifiers

RTRX-RE021-102 (QSC200850)

Identifier Type: -

Identifier Source: org_study_id